tradingkey.logo


tradingkey.logo


TG Therapeutics Inc

TGTX
31.070USD
+0.340+1.11%
終倀 12/24, 16:00ET15分遅れの株䟡
4.82B時䟡総額
10.15盎近12ヶ月PER


TG Therapeutics Inc

31.070
+0.340+1.11%

詳现情報 TG Therapeutics Inc 䌁業名

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

TG Therapeutics Incの䌁業情報


䌁業コヌドTGTX
䌚瀟名TG Therapeutics Inc
䞊堎日Dec 14, 1995
最高経営責任者「CEO」Weiss (Michael S)
埓業員数338
蚌刞皮類Ordinary Share
決算期末Dec 14
本瀟所圚地3020 Carrington Mill Blvd., Suite 475
郜垂MORRISVILLE
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号27560-5435
電話番号18775758489
りェブサむトhttps://www.tgtherapeutics.com/
䌁業コヌドTGTX
䞊堎日Dec 14, 1995
最高経営責任者「CEO」Weiss (Michael S)

TG Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.16M
-33.77%
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
-2.19%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
-18.15%
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.16M
-33.77%
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
-2.19%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%

収益内蚳

通貚: USD曎新時刻: Mon, Oct 6
通貚: USD曎新時刻: Mon, Oct 6
FY2025Q1
FY2024
事業別USD
䌚瀟名
収益
比率
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
事業別USD
䌚瀟名
収益
比率
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%

株䞻

曎新時刻: Mon, Nov 17
曎新時刻: Mon, Nov 17
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
BlackRock Institutional Trust Company, N.A.
11.86%
The Vanguard Group, Inc.
9.75%
Weiss (Michael S)
5.77%
State Street Investment Management (US)
5.10%
ClearBridge Investments, LLC
2.93%
他の
64.59%
株䞻統蚈
株䞻統蚈
比率
BlackRock Institutional Trust Company, N.A.
11.86%
The Vanguard Group, Inc.
9.75%
Weiss (Michael S)
5.77%
State Street Investment Management (US)
5.10%
ClearBridge Investments, LLC
2.93%
他の
64.59%
皮類
株䞻統蚈
比率
Investment Advisor
34.37%
Investment Advisor/Hedge Fund
17.35%
Hedge Fund
7.07%
Individual Investor
6.78%
Research Firm
3.06%
Pension Fund
1.30%
Bank and Trust
0.39%
Family Office
0.13%
Sovereign Wealth Fund
0.06%
他の
29.49%

機関投資家保有株


曎新時刻: Wed, Oct 1
曎新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
698
101.46M
63.91%
-17.24M
2025Q2
693
115.94M
73.03%
-21.56M
2025Q1
704
116.82M
73.80%
-25.76M
2024Q4
657
113.87M
72.65%
-36.14M
2024Q3
598
117.83M
76.11%
-20.28M
2024Q2
544
109.58M
70.90%
-28.91M
2024Q1
535
105.41M
68.45%
-29.01M
2023Q4
542
104.64M
69.13%
-36.73M
2023Q3
552
104.67M
69.33%
-30.54M
2023Q2
543
102.45M
68.58%
-35.33M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
BlackRock Institutional Trust Company, N.A.
19.13M
12.06%
-84.56K
-0.44%
Jun 30, 2025
The Vanguard Group, Inc.
15.77M
9.94%
+203.00K
+1.30%
Jun 30, 2025
Weiss (Michael S)
13.82M
8.71%
--
--
Apr 14, 2025
State Street Investment Management (US)
7.62M
4.8%
+184.34K
+2.48%
Jun 30, 2025
ClearBridge Investments, LLC
3.05M
1.92%
+408.10K
+15.43%
Jun 30, 2025
Soleus Capital Management, L.P.
2.24M
1.41%
-602.77K
-21.17%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.49M
2.2%
+207.89K
+6.33%
Jun 30, 2025
Pictet Asset Management Ltd.
1.91M
1.2%
-489.69K
-20.43%
Jun 30, 2025
Hood River Capital Management LLC
1.57M
0.99%
+11.02K
+0.71%
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Invesco S&P SmallCap Health Care ETF
2.89%
State Street SPDR S&P Biotech ETF
1.93%
Virtus LifeSci Biotech Products ETF
1.49%
Invesco S&P SmallCap 600 Pure Growth ETF
1.44%
Invesco S&P SmallCap Momentum ETF
1.4%
Direxion Daily S&P Biotech Bull 3X Shares
1.11%
State Street SPDR S&P 600 Small Cap Growth ETF
0.65%
First Trust NASDAQ Pharmaceuticals ETF
0.63%
Principal U.S. Small-Cap ETF
0.62%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.61%
詳现を芋る
Invesco S&P SmallCap Health Care ETF
比率2.89%
State Street SPDR S&P Biotech ETF
比率1.93%
Virtus LifeSci Biotech Products ETF
比率1.49%
Invesco S&P SmallCap 600 Pure Growth ETF
比率1.44%
Invesco S&P SmallCap Momentum ETF
比率1.4%
Direxion Daily S&P Biotech Bull 3X Shares
比率1.11%
State Street SPDR S&P 600 Small Cap Growth ETF
比率0.65%
First Trust NASDAQ Pharmaceuticals ETF
比率0.63%
Principal U.S. Small-Cap ETF
比率0.62%
Vanguard S&P Small-Cap 600 Growth Index Fund
比率0.61%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

TG Therapeutics Incの䞊䜍5名の株䞻は誰ですか


TG Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。
BlackRock Institutional Trust Company, N.A.は19.13M株を保有しおおり、これは党䜓の12.06%に盞圓したす。
The Vanguard Group, Inc.は15.77M株を保有しおおり、これは党䜓の9.94%に盞圓したす。
Weiss (Michael S)は13.82M株を保有しおおり、これは党䜓の8.71%に盞圓したす。
State Street Investment Management (US)は7.62M株を保有しおおり、これは党䜓の4.80%に盞圓したす。
ClearBridge Investments, LLCは3.05M株を保有しおおり、これは党䜓の1.92%に盞圓したす。

TG Therapeutics Incの株䞻タむプ䞊䜍3皮は䜕ですか


TG Therapeutics Incの株䞻タむプ䞊䜍3皮は、
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Weiss (Michael S)

TG Therapeutics IncTGTXの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、TG Therapeutics Incの株匏を保有しおいる機関は698瀟あり、保有株匏の総垂堎䟡倀は玄101.46Mで、党䜓の63.91%を占めおいたす。2025Q2ず比范しお、機関の持ち株は-9.12%増加しおいたす。

TG Therapeutics Incの最倧の収益源は䜕ですか


FY2025Q1においお、Total product revenue, net郚門がTG Therapeutics Incにずっお最倧の収益を生み出しおおり、その金額は119.66Mで、党収益の99.01%を占めおいたす。
KeyAI
î™